Completed PHASE2 INTERVENTIONAL NCT01243632

Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment

A Phase II Trial of Low-dose Gemcitabine in Prolonged Infusion and Cisplatin in Treatment of Malignant Pleural Mesothelioma

Sponsor: Institute of Oncology Ljubljana

Conditions Malignant Pleural Mesothelioma

Interventions Prolonged 6-hr infusion of gemcitabine

Updated 5 times since 2017 Last updated: Nov 17, 2010 Started: Dec 31, 2002 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Malignant Pleural Mesothelioma and is currently completed. Institute of Oncology Ljubljana leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Oncology Ljubljana
Ministry of Higher Education, Science and Technology, Solvenia

Data source: Institute of Oncology Ljubljana

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ljubljana, Slovenia